BC Innovations | Aug 23, 2019
Distillery Techniques

Fecal levels of bacterial genes, metabolite in neonates as childhood allergic disease biomarker

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling Neonatal fecal abundance of three bacterial epoxide hydrolase genes as well as their lipid-derived metabolite 12,13-diHOME could predict childhood development of allergic diseases including asthma, eczema and...
BC Innovations | Mar 4, 2019
Distillery Therapeutics

Inhibiting soluble epoxide hydrolase for renal damage

DISEASE CATEGORY: Renal INDICATION: Renal damage Mouse studies suggest inhibiting soluble epoxide hydrolase could help treat renal damage. In a mouse model of diet-induced renal injury, a soluble epoxide hydrolase inhibitor tool compound decreased renal...
BC Innovations | Nov 9, 2018
Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
BC Innovations | Dec 19, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Diabetic retinopathy Patient samples and mouse studies suggest inhibiting EPHX2 could help treat non-proliferative diabetic retinopathy (NPDR). In postmortem retinal tissue samples from patients, high levels of EPHX2 were associated with disease severity. In...
BC Innovations | Nov 27, 2017
Distillery Therapeutics


INDICATION: Renal damage Mouse studies suggest 14,15-epoxyeicosatrienoic acid (EET) or inhibition of its catabolic enzyme EPHX2 could help treat acute kidney injury (AKI). In a mouse model of AKI, 14,15-EET decreased kidney injury and increased...
BC Innovations | Apr 25, 2017
Distillery Therapeutics


INDICATION: Periodontitis Studies in mice suggest inhibiting epoxide hydrolase could help treat periodontal bone loss. In a mouse model of bacterial infection-induced periodontitis, a previously reported epoxide hydrolase inhibitor decreased alveolar bone loss compared with...
BC Innovations | Dec 3, 2015
Targets & Mechanisms

The two faces of LTA4H

Although the enzyme LTA4H has long been considered a driver of inflammatory diseases, companies have yet to create an inhibitor that succeeds in the clinic beyond Phase II. That could be due to a secondary,...
BioCentury | Aug 18, 2014

Breathing room

AstraZeneca plc 's acquisition of Almirall S.A. 's respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination...
BC Innovations | Jun 19, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Epoxide hydrolase Mouse studies identified a soluble epoxide hydrolase-dependent mechanism by which a Mediterranean diet protects against hypertension. Mediterranean diet components form nitro...
BC Innovations | Apr 25, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Epoxide hydrolase 2 (EPHX2; CEH) Cell culture and mouse studies suggest a combination of fish oil-derived epoxy docosapentaenoic acids (EDPs) and EPHX2 inhibitors could...
Items per page:
1 - 10 of 27